Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- DRMA
- Price
- 1.26
- Stock movement down
- -0.03 (-2.33%)
- Company name
- Dermata Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.57M
- Ent value
- 19.71K
- Price/Sales
- -
- Price/Book
- 0.90
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -88.85%
- 3 year return (CAGR)
- -87.84%
- 5 year return (CAGR)
- 39.33%
- 10 year return (CAGR)
- 18.04%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
DRMA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.90 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 2.84M |
| EPS (TTM) | -8.62 |
| FCF per share (TTM) | -9.10 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -9.07M |
| Net income (TTM) | -8.85M |
| EPS (TTM) | -8.62 |
| EPS (1y forward) | -3.01 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.66M |
| Net receivables | 0.00 |
| Total current assets | 5.07M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 5.07M |
| Accounts payable | 453.43K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 1.11M |
| Total liabilities | 1.11M |
| Shareholder's equity | 3.96M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -9.34M |
| Capital expenditures (TTM) | 13.00 |
| Free cash flow (TTM) | -9.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -223.42% |
| Return on Assets | -174.46% |
| Return on Invested Capital | -223.42% |
| Cash Return on Invested Capital | -235.90% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.28 |
| Daily high | 1.32 |
| Daily low | 1.21 |
| Daily Volume | 144K |
| All-time high | 1500000.00 |
| 1y analyst estimate | 10.00 |
| Beta | 0.55 |
| EPS (TTM) | -8.62 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| DRMA | S&P500 | |
| Current price drop from All-time high | -100.00% | -1.82% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 17 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -82.92% | -10.84% |
| Avg time to new high | 91 days | 12 days |
| Max time to new high | 1519 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
3.57M
Marketcap category
Small-cap
Description
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Employees
8
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page